Outset Medical, Inc.

Outset Medical, Inc.

NNASDAQ:OM
3.39
USD
-0.34
(-9.12%)
-3.86EPS
56.62MMarket Cap
Feb 17Next Earn
Outset Medical, Inc.
NASDAQ:OM
(Nasdaq Stock Market)

Recent

price

3.39

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
1
7.52
45.79
33.76
35.93
39.44
32.83
7.85
6.63
Revenue per Share
-24.82
-34.06
-111.41
-43.41
-50.75
-52.27
-36.95
-5.37
-3.86
Basic EPS, GAAP
-24.04
-36.69
-99.15
-43.88
-47.98
-40.78
-33.84
-3.1
-2.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-109.06
-140.97
115.38
118.78
76.13
36.63
7.6
6.99
4.41
Book Value per Share
-109.06
-140.97
115.38
118.78
76.13
36.63
7.6
6.99
4.41
Tangible Book Value per Share
2
2
1
3
3
3
3
15
18
Basic Weighted Avg Shares
2
15
50
103
115
130
114
119
122
Sales/Revenue/Turnover
-2,320.03
-466.29
-235.24
-127.21
-139.56
-130.22
-99.72
-55.83
-51.24
Operating Margin (%)
1
1
3
5
5
6
6
4
3
Depreciation Expense
-50
-68
-121
-132
-163
-173
-128
-82
-71
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2,480.32
-452.97
-243.3
-128.59
-141.24
-132.54
-112.57
-68.34
-58.33
Profit Margin (%)
137
55
309
358
322
236
213
213
172
Working Capital
28
22
38
37
102
135
200
100
102
LT Debt
-288
-372
329
374
246
123
27
127
83
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-37.55
-52.56
-93.69
-170.97
-106.2
-64.14
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
3
2
LT Borrowings
97
98
98
LT Finance Leases
3
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
71
81
57

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
237
228
216
Cash, Cash Equivalents & STI
157
147
137
Accounts Receivable, Net
25
29
30
Inventories
50
47
45
Total Current Liabilities
38
44
44
Payables & Accruals
9
12
13
ST Debt
2
3
2
Deferred Revenue
13
14
13

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
44.95%
373.37%
Free Cash Flow
- -
-9.3%
-59.8%
Net Income, GAAP
- -
-4.8%
-36.2%
Sales/Revenue/Turnover
- -
24.64%
5.09%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28
27
29
29
114
2025
30
31
29
29
119
2026
28
32
34
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-11.77
-9.96
-8.3
-7.29
-36.95
2025
-3.66
-1.04
-1
-1.09
-5.37
2026
-1.03
-0.97
-0.78
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Outset Medical Outset Medical, Inc. (OM) is a medical technology company that develops and commercializes the Tablo Hemodialysis System, an all-in-one, connected platform designed to simplify dialysis treatments across the care continuum from hospital ICUs and outpatient clinics to home settings; the system supports multiple modalities including hemodialysis, features automated setup and teardown processes, cloud-based data streaming for remote monitoring and reporting, and rapid training capabilities for nurses in hours and patients in days. Headquartered in San Jose, California, and founded in 2003, the company manufactures in North America and primarily operates throughout the United States, targeting healthcare providers, hospitals, dialysis clinics, and end-stage renal disease patients with its innovative renal care solutions that aim to reduce costs, complexity, and improve patient outcomes through clinical versatility and digital health integration. In early 2025, Outset Medical announced a one-for-fifteen reverse stock split effective March 20 to reduce shares outstanding and support strategic objectives; later in January 2025, it secured up to $169 million in private placement financing led by Perceptive Advisors and others including T. Rowe Price and Durable Capital Partners LP, alongside a new $100 million term loan facility maturing in 2030 to retire $200 million in prior debt, enhancing its liquidity to approximately $210 million post-transaction while reporting preliminary 2024 revenues of $113 million.

Company News

  • All You Need to Know About Outset Medical (OM) Rating Upgrade to Buy

  • Outset Medical (NASDAQ:OM) Stock Breaks Above 200 Day Moving Average – Here’s What Happened

  • Outset Medical Q3 Earnings Call Highlights

  • Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates

  • Outset Medical Reports Third Quarter 2026 Results

  • Outset Medical to Participate in the 2026 Stifel Healthcare Conference

  • Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

  • Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock

  • Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript

  • Outset Medical Q2 Earnings Call Highlights

  • Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

  • Outset Medical Reports Second Quarter 2026 Results

  • Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

  • Outset Medical, Inc. (NASDAQ: OM) Investor Alert: Schubert Jonckheer Investigating Possible False Statements, Over $50 Million in Insider Sales

  • Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?

  • OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026

  • Osisko Intersects 80 Metres Averaging 1.93% Cu at Gaspé